Two types of vulvar squamous cell carcinomas (VSCCs) are recognized according to their relationship to human papillomavirus (HPV). Basaloid or warty carcinomas are considered HPV-associated tumors, whereas differentiated keratinizing neoplasms are considered non-HPV-associated. Recently, immunohistochemical detection of p16 and p53 has been proposed to differentiate these 2 types of VSCCs. We conducted a histologic study with immunohistochemical evaluation of p16 and p53 and HPV detection and typing by polymerase chain reaction using 2 different sets of primers in 92 cases of VSCCs to evaluate the usefulness of immunohistochemistry in the classification of VSCCs and to describe the clinico-pathologic characteristics of both types of VSCCs. HPV was detected in 16/92 (17.4%) specimens, HPV16 being identified in 75% of positive cases. A significant number of discrepancies between histology and HPV detection were observed, with 37.5% of HPV-positive tumors being keratinizing and 9.2% of HPV-negative carcinomas showing basaloid or warty features. Diffuse positivity for p16 and p53 was observed in 100% and 6.2% of HPV-positive tumors and in 2.3% and 64.5% of HPV-negative neoplasms, respectively. The sensitivity and specificity of p16 immunostaining to detect HPV-associated carcinomas (100% and 98.7%, respectively) were better than those of histologic criteria (93.8% and 35.5%) and of p53 negative stain (62.5% and 93.4%). Vulvar intraepithelial neoplasia grade 3 of basaloid/warty type was identified in 53.8% HPV-positive tumors, including 3 keratinizing tumors. All these cases were p16 positive and p53 negative. Vulvar intraepithelial neoplasia grade 3 of differentiated type was observed in 45.6% of HPV-negative cases; 90.8% of them were positive for p53 but all were negative for p16. No differences in age, stage, or development of recurrence were observed between HPV-positive and negative tumors. In summary, the current morphologic criteria to discriminate HPV-positive and negative VSCCs have a significant overlap. Immunostaining for p16 is a reliable marker for HPV-positive VSSCs, which improves the results of histologic classification.
Objective: To assess the natural evolution of low-grade squamous intraepithelial lesions (LSIL) in a retrospective study conducted in a specialized primary care setting of patients detected from the cervical cancer prevention program. Materials and Methods: A review of all cytological examinations between January and December 2002, with 24 months follow-up was conducted in LSIL patients. Follow-up with cytological testing and colposcopy were performed every 6 months, and a biopsy was performed in cases that were indicated by protocol. Patients were not systemically or topically treated in any case. Results: During the study period, 4,152 women received cytology testing, and 122 had LSIL (prevalence, 2.9%). One hundred eleven patients (91%) completed the follow-up, and the remaining patients were lost for various reasons. The age distribution was as follows: 3.2% (G20 years), 34.4% (20Y29 years), 25.4% (30Y39 years), 27.2% (40Y49 years), 9% (50Y59 years), and 0.8% (960 years). Spontaneous regression was observed in 79 (71.3%) of women who completed follow-up. Regression was observed in 51.8% of patients within 12Y18 months and in 48.2% of patients within 18Y24 months of cytological testing. Regression according to age group was as follows: 100% (G20 years), 79.5% (20Y29 years), 60.6% (30Y39 years), 81.8% (40Y49 years), 90.9% (50Y59 years), and 100% (960 years). Conclusions: The general tendency of natural regression in LSIL patients without any specific risk factors identified is supported by our results. 2007, American Society for Colposcopy and Cervical Pathology
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.